Alpha-1 proteinase inhibitor (human) second generation is under clinical development by Kamada Pharmaceuticals and currently in Phase II for Alpha-1 Antitrypsin Deficiency (A1AD). According to GlobalData, Phase II drugs for Alpha-1 Antitrypsin Deficiency (A1AD) have a 33% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how Alpha-1 proteinase inhibitor (human) second generation’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
Alpha-1 proteinase inhibitor (human) second generation overview
Alpha-1 proteinase inhibitor (human) is under development for the treatment of alpha- antitrypsin deficiency (inherited emphysema) and bronchiectasis. It is administered through inhalation using e-Flow based inhalation device. The drug candidate is a second generation AAT product. The development of drug candidate is based on e-Flow aerosol technology. It was also under development for cystic fibrosis.
Kamada Pharmaceuticals overview
Kamada Pharmaceuticals (Kamada), is a biopharmaceutical company that develops, manufactures, and commercializes specialty proteins, specific immunoglobulins, and other prescription medicines. Its major products include respiratory, immunoglobins, critical care, and others. It also offers medicines for the treatment of cystic fibrosis, asthma, hemophilia, rabies, hepatitis B and other indications. Kamada’s pipeline products include intravenous and inhaled AAT protein and rabies. Its intravenous formulations are intended for Graft vs Host Disease (GVHD), type-1 diabetes, covid-19, and lung transplantation indications. The company distributes its products through a network of distributors in Brazil, Israel, Russia, India, and other countries in Eastern Europe, Latin America, and Asia regions. Kamada is headquartered in Rehovot, Israel.
For a complete picture of Alpha-1 proteinase inhibitor (human) second generation’s drug-specific PTSR and LoA scores, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.
